GSK (GSK) Increases Yet Falls Behind Market: What Investors Need to Know
https://www.zacks.com/stock/news/2243108/gsk-gsk-increases-yet-falls-behind-market-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2243108
Mar 19, 2024 - In the most recent trading session, GSK (GSK) closed at $42.32, indicating a +0.43% shift from the previous trading day.
0
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035
Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
0
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
https://www.zacks.com/stock/news/2242368/immuneering-imrx-plummets-71-in-one-week-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2242368
Mar 18, 2024 - Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
0
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446
Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
0
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
https://www.zacks.com/stock/news/2240861/pfizer-pfe-gets-eu-nod-for-expanded-use-of-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240861
Mar 14, 2024 - Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
0
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
https://www.zacks.com/stock/news/2240226/allogene-allo-inks-deal-with-arbor-bio-for-crispr-technology?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240226
Mar 13, 2024 - Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
0
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
https://www.zacks.com/stock/news/2240223/regulus-rgls-up-71-on-topline-data-from-kidney-disease-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240223
Mar 13, 2024 - Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
0
Inflation Remains Sticky in February: 5 Safe Picks
https://www.zacks.com/stock/news/2240004/inflation-remains-sticky-in-february-5-safe-picks?cid=CS-ZC-FT-analyst_blog|investment_ideas-2240004
Mar 13, 2024 - We have narrowed our search to five low-beta stocks with a solid dividend yield. These are: TAP, TSN, TM, GSK and BAH.
0
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2239919/has-gsk-plc-sponsored-adr-gsk-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2239919
Mar 13, 2024 - Here is how GSK (GSK) and Capricor Therapeutics (CAPR) have performed compared to their sector so far this year.
0
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
https://www.zacks.com/stock/news/2237558/emergent-ebs-down-16-on-q4-earnings-miss-tops-on-sales?cid=CS-ZC-FT-analyst_blog|earnings_article-2237558
Mar 07, 2024 - Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
0